Name

Yuanbio Ventures

Legal name

Suzhou Industrial Park Yuan Fu Venture Capital Limited Partner

Website

https://en.bioventure.com.cn

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

NAICS

Portfolio Management and Investment Advice (52394), Miscellaneous Financial Investment Activities (523999)

SIC

Investment Advice (6282)

akta.pro primary industry

Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)

Keywords

• Healthcare venture capital
• Biotech investment
• Medical device investment
• Venture capital fund management
• Early stage investment

Headquarters

HQ city

Suzhou

HQ country

China

HQ region

Asia

Offices5 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations

Revenue model

1. Management Fees: VC firms typically charge management fees on committed capital during the investment period to cover operations.
2. Carried Interest: Profit participation from successful portfolio company exits (IPOs, M&A, secondary sales) generating returns for fund LPs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

YuanBio Venture Capital is a healthcare-focused venture capital firm that manages multiple investment funds (YuanBio Fund I, YuanBio USD Fund II) and provides early and growth stage equity investment to innovative healthcare companies across biotech, medical devices, IVD, and healthcare services. The firm invests capital and provides post-investment value-added services including business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies.

Product overview

YuanBio Venture Capital is a leading healthcare investment firm offering investment fund management services across four key sectors: biotech/biopharmaceuticals, medical devices, in vitro diagnostics (IVD), and healthcare services. The firm operates multiple fund vehicles (YuanBio Fund I, YuanBio USD Fund II) and has built a portfolio of over 200 companies. Their investment strategy focuses on early and growth stage opportunities with high entry barriers through technology IP, targeting cancer, diabetes, and cardiac disease therapeutics. The firm's value-added services include business development support, management assistance, fundraising facilitation, and team recruitment for portfolio companies. The investment operations are structured around portfolio categories (BioPharma, Medical Device, IVD, Health Services), with each category containing multiple invested companies.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

• 19 portfolio companies listed on STAR Board, HKEX, and Nasdaq
• +3 more outcomes

Named customers27 records

Segments4 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

One partnership is on record.

• BioBay (苏州生物纳米园)coreStrategic or Co-development PartnerBioBay is YuanBio's core LP and fund sponsor. Located in Suzhou Industrial Park, BioBay brings high-quality deal flow and serves as an information exchange platform. BioBay is a core driver of post-investment value-added services to portfolio companies.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• 5Y Capital (formerly Morningside Venture Capital): China-focused venture firm with healthcare among its core verticals. Has co-invested alongside YuanBio in rounds like Allink Biotherapeutics, and represents an alternative for LPs seeking a fund manager with both healthcare and technology breadth.
• IDG Capital: One of the earliest foreign-invested venture capital firms in China, with a dedicated healthcare practice covering biotech, medical devices, and precision medicine. While broader in mandate, IDG competes for the same Chinese healthcare growth-stage opportunities as YuanBio.
• CDH Investments: Large Chinese alternative asset manager with a dedicated healthcare practice (RMB 1B fund) and prior follow-on investments in YuanBio portfolio companies (Suzhou Pioneer Pharmaceutical $10M from CDH). Broader mandate but directly overlaps in healthcare growth-stage deals.
• Hillhouse Capital: Large China- and Asia-focused investment manager with a substantial healthcare practice alongside consumer and tech investing. While broader than YuanBio, Hillhouse competes for top Chinese healthcare deals and offers institutional LPs an alternative to a pure-play healthcare specialist.
• OrbiMed: Global healthcare-dedicated investment firm operating in China with comparable biotech, medtech and diagnostics coverage. Provides an international pure-play alternative to YuanBio for institutional LPs evaluating China healthcare exposure.

Direct peers

• Qiming Venture Partners: One of China's leading healthcare- and technology-focused venture capital firms with a comparable early/growth-stage healthcare practice. Directly competes with YuanBio for healthcare deal flow in China and has similarly demonstrated a strong IPO track record across biotech and medical devices.
• Centurium Capital: Greater China-focused healthcare and growth investor that co-led Excalipoint Therapeutics' extension round with YuanBio. Directly comparable in sector focus and stage strategy, often appearing alongside YuanBio in late-seed/Series A biotech syndicates.
• Legend Capital: China-headquartered venture capital firm with a dedicated healthcare/biotech practice and comparable AUM scale. Legend Capital has co-invested with YuanBio on recent transactions such as Allink Biotherapeutics, making it a direct competitor and frequent co-investor in Chinese healthcare deals.
• Apricot Capital: Healthcare-focused investor that co-led the $41M initial seed round of Excalipoint Therapeutics with YuanBio. Operates a Chinese healthcare mandate at comparable fund size, making it a direct competitor in biotech early-stage financing.
• LYFE Capital (LAV): Healthcare-dedicated venture capital firm active in China with a focus on innovative therapeutics and medical devices. LYFE participated alongside YuanBio in the Excalipoint Therapeutics extension round, and its fund-stage and sector focus closely parallel YuanBio's strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yuanbio Ventures